866-997-4948(US-Canada Toll Free)

Mixed Dyslipidemia - Pipeline Review, H2 2013

Published By :

Global Markets Direct

Published Date : Dec 2013

Category :

Metabolic Disorders

No. of Pages : 63 Pages


Global Markets Directs, \'Mixed Dyslipidemia Pipeline Review, H2 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Mixed Dyslipidemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Mixed Dyslipidemia. Mixed Dyslipidemia Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Mixed Dyslipidemia.
  • A review of the Mixed Dyslipidemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Mixed Dyslipidemia pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Mixed Dyslipidemia.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Mixed Dyslipidemia pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Mixed Dyslipidemia Overview 7
Therapeutics Development 8
Pipeline Products for Mixed Dyslipidemia - Overview 8
Pipeline Products for Mixed Dyslipidemia - Comparative Analysis 9
Mixed Dyslipidemia - Therapeutics under Development by Companies 10
Mixed Dyslipidemia - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Mixed Dyslipidemia - Products under Development by Companies 15
Mixed Dyslipidemia - Companies Involved in Therapeutics Development 16
Amgen Inc. 16
Pfizer Inc. 17
Pronova BioPharma ASA 18
Intas Pharmaceuticals Ltd. 19
Catabasis Pharmaceuticals, Inc. 20
Matinas BioPharma, Inc. 21
CymaBay Therapeutics, Inc. 22
Mixed Dyslipidemia - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Target 24
Assessment by Mechanism of Action 26
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Assessment by Therapeutic Class 32
Drug Profiles 34
evolocumab - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
bococizumab - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
INSUPR-001 DR - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
MBX-8025 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
PRC-4016 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
CAT-2003 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
MAT-9001 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Mixed Dyslipidemia - Recent Pipeline Updates 44
Mixed Dyslipidemia - Dormant Projects 52
Mixed Dyslipidemia - Discontinued Products 53
Mixed Dyslipidemia - Product Development Milestones 54
Featured News & Press Releases 54
Dec 19, 2013: Amgen Announces Positive Top-Line Results From 52-Week Phase 3 DESCARTES Study Of Evolocumab In Patients With High Cholesterol 54
Oct 16, 2013: Amarin Announces FDA Advisory Committee Outcome for the Use of Vascepa in the Treatment of High Triglycerides With Mixed Dyslipidemia 55
Aug 28, 2013: Catabasis to Present Phase 1 Data from Oral SMART Linker Conjugate CAT-2003 at Upcoming Conference 56
Jun 21, 2013: Amarin Announces FDA Acceptance Of Supplemental New Drug Application For Vascepa For Treatment Of Patients With High Triglycerides With Mixed Dyslipidemia 56
Apr 30, 2013: Amarin Announces Approval Of Supplemental New Drug Application For BASF As Additional Vascepa Active Pharmaceutical Ingredient Supplier 57
Apr 23, 2013: Amarin Announces FDA Acceptance Of sNDA For Vascepa For Treatment Of Patients With High Triglycerides With Mixed Dyslipidemia 57
Mar 07, 2013: Kowa Pharma And Lilly Announce Results Of Study Evaluating Efficacy Of Livalo In HIV-infected Adults With Dyslipidemia 58
Feb 26, 2013: Amarin Submits Supplemental New Drug Application For Vascepa For Treatment Of Patients With High Triglycerides With Mixed Dyslipidemia 59
Jan 11, 2013: MSD Provides Update On Next Steps For Tredaptive 59
Dec 21, 2012: European Medicines Agency Starts Review Of Merck\'s Tredaptive, Pelzont And Trevaclyn 60

Appendix 62
Methodology 62
Coverage 62
Secondary Research 62
Primary Research 62
Expert Panel Validation 62
Contact Us 63
Disclaimer 63

List of Table


Number of Products under Development for Mixed Dyslipidemia, H2 2013 8
Number of Products under Development for Mixed Dyslipidemia - Comparative Analysis, H2 2013 9
Number of Products under Development by Companies, H2 2013 11
Comparative Analysis by Late Stage Development, H2 2013 12
Comparative Analysis by Clinical Stage Development, H2 2013 13
Comparative Analysis by Early Stage Development, H2 2013 14
Products under Development by Companies, H2 2013 15
Mixed Dyslipidemia - Pipeline by Amgen Inc., H2 2013 16
Mixed Dyslipidemia - Pipeline by Pfizer Inc., H2 2013 17
Mixed Dyslipidemia - Pipeline by Pronova BioPharma ASA, H2 2013 18
Mixed Dyslipidemia - Pipeline by Intas Pharmaceuticals Ltd., H2 2013 19
Mixed Dyslipidemia - Pipeline by Catabasis Pharmaceuticals, Inc., H2 2013 20
Mixed Dyslipidemia - Pipeline by Matinas BioPharma, Inc., H2 2013 21
Mixed Dyslipidemia - Pipeline by CymaBay Therapeutics, Inc., H2 2013 22
Assessment by Monotherapy Products, H2 2013 23
Number of Products by Stage and Target, H2 2013 25
Number of Products by Stage and Mechanism of Action, H2 2013 27
Number of Products by Stage and Route of Administration, H2 2013 29
Number of Products by Stage and Molecule Type, H2 2013 31
Number of Products by Stage and Therapeutic Class, H2 2013 33
Mixed Dyslipidemia Therapeutics - Recent Pipeline Updates, H2 2013 44
Mixed Dyslipidemia - Dormant Projects, H2 2013 52
Mixed Dyslipidemia - Discontinued Products, H2 2013 53

List of Chart


Number of Products under Development for Mixed Dyslipidemia, H2 2013 8
Number of Products under Development for Mixed Dyslipidemia - Comparative Analysis, H2 2013 9
Number of Products under Development by Companies, H2 2013 10
Assessment by Monotherapy Products, H2 2013 23
Number of Products by Top 10 Target, H2 2013 24
Number of Products by Stage and Top 10 Target, H2 2013 25
Number of Products by Top 10 Mechanism of Action, H2 2013 26
Number of Products by Stage and Top 10 Mechanism of Action, H2 2013 27
Number of Products by Top 10 Route of Administration, H2 2013 28
Number of Products by Stage and Top 10 Route of Administration, H2 2013 29
Number of Products by Top 10 Molecule Type, H2 2013 30
Number of Products by Stage and Top 10 Molecule Type, H2 2013 31
Number of Products by Top 10 Therapeutic Class, H2 2013 32
Number of Products by Stage and Top 10 Therapeutic Class, H2 2013 33

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *